205 related articles for article (PubMed ID: 28212926)
1. Comorbidity influences therapeutic approach in multiple sclerosis.
Capone F; Ferraro E; Florio L; Marcoccia A; Di Lazzaro V; Di Battista G
Clin Neurol Neurosurg; 2017 Apr; 155():14-16. PubMed ID: 28212926
[No Abstract] [Full Text] [Related]
2. [Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis].
Popova EV; Boyko AN; Orlova EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):68-72. PubMed ID: 28139614
[TBL] [Abstract][Full Text] [Related]
3. NICE approval of dimethyl fumarate could benefit thousands living with relapsing-remitting multiple sclerosis.
Boulicault D; Duddy M
Neurodegener Dis Manag; 2015; 5(1):7-10. PubMed ID: 25711449
[No Abstract] [Full Text] [Related]
4. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
Chevalier J; Chamoux C; Hammès F; Chicoye A
PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055
[TBL] [Abstract][Full Text] [Related]
5. [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis].
Shmidt TE
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):140-145. PubMed ID: 29265100
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism in multiple sclerosis: a report of two cases with pulmonary embolism on dimethyl fumarate and available data from adverse event reporting systems. Time to include disease modifying drugs in the equation?
Papathanasiou A; Abdel-Fahim R; Gilmore C; Evangelou N
Clin Neurol Neurosurg; 2020 May; 192():105726. PubMed ID: 32062308
[No Abstract] [Full Text] [Related]
7. [Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis].
Alifirova VM; Boiko AN; Vlasov YV; Davydovskaya MV; Zakharova MN; Malkova NA; Popova EV; Sivertseva SA; Spirin NN; Khachanova NV; Shmidt ТЕ
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(1):97-102. PubMed ID: 28252608
[TBL] [Abstract][Full Text] [Related]
8. Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
Harmel P; Schlunk F; Harms L
Mult Scler; 2018 Jul; 24(8):1131-1133. PubMed ID: 29708444
[TBL] [Abstract][Full Text] [Related]
9. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.
Losavio FA; Lucchini M; De Fino C; Mirabella M; Nociti V
Mult Scler Relat Disord; 2016 May; 7():68-9. PubMed ID: 27237761
[TBL] [Abstract][Full Text] [Related]
10. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
Blair HA
Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875
[TBL] [Abstract][Full Text] [Related]
11. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.
Yadav SK; Soin D; Ito K; Dhib-Jalbut S
J Mol Med (Berl); 2019 Apr; 97(4):463-472. PubMed ID: 30820593
[TBL] [Abstract][Full Text] [Related]
12. The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
Khatri BO; Garland J; Berger J; Kramer J; Sershon L; Olapo T; Sesing J; Dukic M; Rehn E
Mult Scler Relat Disord; 2015 Jul; 4(4):377-9. PubMed ID: 26195059
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
14. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
Dorman E; Kansal AR; Sarda S
J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
[TBL] [Abstract][Full Text] [Related]
15. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
Deeks ED
Drugs; 2016 Feb; 76(2):243-54. PubMed ID: 26689201
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
Su W; Kansal A; Vicente C; Deniz B; Sarda S
J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
[TBL] [Abstract][Full Text] [Related]
17. Desensitization for immediate hypersensitivity to oral dimethyl fumarate (Tecfidera).
Di Bona D; Albanesi M; Giliberti LA; Nico A; Rossi MP; Caiaffa MF; Macchia L
J Allergy Clin Immunol Pract; 2017; 5(3):821-822. PubMed ID: 27888036
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
20. Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
Luo H; Bhatt H; Mohamad S; Uhrik E; Sen S; Mathew T; Yousif A
J Neurol; 2015 Mar; 262(3):779-80. PubMed ID: 25626723
[No Abstract] [Full Text] [Related]
[Next] [New Search]
